{"entity":{"id":"nct01986569","kind":"trial","name":"Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer","aka":[],"tldr":"A phase 3 trial of FES PET in Breast cancer, run by Asan Medical Center, completed.","summary":"Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT01986569 by Asan Medical Center, with 93 participants recorded, started 2013-11 and reaching its primary completion in 2016-11. Interventions recorded: [18F]fluoroestradiol (FES). Conditions recorded: Recurrent Breast Cancer, Stage IV Breast Cancer.\n\nLinked to the technology FES PET because the registry's title names it (\"18f fluoroestradiol pet\") and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01986569","url":"https://clinicaltrials.gov/study/NCT01986569"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":["fes-pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01986569","phase":"3","setting":"A Phase III, Open Label, Non-randomized, Single Center Study to Evaluate Diagnostic Accuracy and Safety of Fluorine-18 (18F) Fluoroestradiol PET/CT in the Assessment of ER Status of Recurrent or Metastatic Lesions in Patients With Breast Cancer","sponsor":"Asan Medical Center","enrolled":93,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01986569/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"technology":[{"id":"fes-pet","kind":"technology","name":"FES PET (oestrogen receptor imaging)","route":"/technologies/fes-pet/"}]}}